Goldman Sachs has downgraded ICON Public Limited Company to a Neutral rating from Buy, reducing its price target from $250 to $200. ICON specializes in healthcare intelligence and clinical research, offering outsourced services to pharmaceutical, biotechnology, and medical device sectors, among others. Its comprehensive services include clinical research, consulting, and real-world intelligence, aimed at accelerating the market entry of new drugs and devices.